文献速递炎症性肠病

系统综述:克罗恩病随机试验的结局与不良事件

Systematic review: outcomes and adverse events from randomised trials in Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2019-03-03

该系统综述检索至2015年11月,纳入181项成人克罗恩病随机对照试验(110项诱导、71项维持),共23850例患者,分析疗效与安全性结局指标。结果显示临床疗效终点报告占92.3%,克罗恩病活动指数(CDAI)主导结局定义(63.5%的试验,含35种应答或缓解定义),客观炎症指标与患者报告结局报告率上升但异质性强、缺乏标准化。

要点

  • 181项随机对照试验中92.3%报告临床疗效终点,CDAI定义应答或缓解者占63.5%。
  • CDAI<150为最常见终点但报告比例从46.4%降至41.1%,CDAI100使用从16.8%升至30.4%。
  • 生物标志物、内镜和组织学终点报告率上升但异质性强,瘘管试验中罕见报告。

核心结论

  • 试验终点随研究和时间变化,瘘管研究终点的定义不同,尽管客观炎症指标和患者报告结局报告增加,但仍缺乏标准化,证实需要为克罗恩病比较效果研究制定核心结局集。

研究设计与样本

  • 系统综述检索MEDLINE、EMBASE、CINAHL和Cochrane Library至2015年11月,纳入成人克罗恩病患者接受药物或手术治疗的随机对照试验,按发表时间(2009年前和2009年起)分层提取疗效与安全性结局、终点定义和测量工具。
  • 共纳入181项随机对照试验(110项诱导试验和71项维持试验),包括23850例患者。

主要发现

  • 92.3%的试验报告临床疗效终点,CDAI在63.5%的试验中定义临床应答或缓解,共含35种应答或缓解定义。
  • CDAI<150是最常见终点,但报告比例从2009年前的46.4%降至2009年起的41.1%,而CDAI100的使用从16.8%升至30.4%。
  • 瘘管研究最常报告瘘管闭合(9项,90.0%)。
  • 生物标志物、内镜和组织学终点的报告总体增加(分别从33.3%升至40.6%、从14.4%升至30.4%、从3.2%升至12.5%),但异质性强,且在瘘管试验中罕见报告。
  • 患者报告结局测量在41.4%的试验中报告,安全性终点在35.4%的试验中报告,许多常见不良事件与疾病加重或治疗失败相关。

关键数值与推荐

  • CDAI<150为最常见终点,报告比例从2009年前的46.4%降至2009年起的41.1%。
  • CDAI100的使用从2009年前的16.8%升至2009年起的30.4%。
  • 瘘管研究中瘘管闭合报告率为90.0%(9项)。
  • 生物标志物、内镜和组织学终点报告率分别从33.3%升至40.6%、从14.4%升至30.4%、从3.2%升至12.5%。
  • 患者报告结局测量报告率为41.4%,安全性终点报告率为35.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The suitability of disease activity indices has been challenged, with growing interest in objective measures of inflammation. AIM: To undertake a systematic review of efficacy and safety outcomes in placebo-controlled randomised controlled trials (RCTs) of patients with Crohn's disease. METHODS: MEDLINE, EMBASE, CINAHL and Cochrane Library were searched until November 2015, for RCTs of adult Crohn's disease patients treated with medical or surgical therapies. Data on efficacy and safety outcomes, end-point definitions, and measurement instruments were extracted and stratified by publication date (pre-2009 and 2009 onwards). RESULTS: One hundred and eighty-one RCTs (110 induction and 71 maintenance) were identified, including 23 850 patients. About 92.3% reported clinical efficacy endpoints. The Crohn's Disease Activity Index (CDAI) dominated, defining clinical response or remission in 63.5% of trials (35 definitions of response or remission). CDAI < 150 was the commonest endpoint, but reporting reduced between periods (46.4%-41.1%), whilst use of CDAI100 increased (16.8%-30.4%). Fistula studies most commonly reported fistula closure (9, 90.0%). Reporting of biomarker, endoscopy and histology endpoints increased overall (33.3%-40.6%, 14.4%-30.4% and 3.2%-12.5%, respectively), but were heterogeneous and rarely reported in fistula trials. Patient-reported outcome measures were reported in 41.4% of trials and safety endpoints in 35.4%. Many of the common adverse events relate to disease exacerbation or treatment failure. CONCLUSIONS: Trial endpoints vary across studies, over time and are distinct in fistula studies. Despite growth in reporting of objective measures of inflammation and in patient-reported outcome measures, there is a lack of standardisation. This confirms the need for a core outcome set for comparative effectiveness research in Crohn's disease.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Catt H, Hughes D, Kirkham JJ, et al. Systematic review: outcomes and adverse events from randomised trials in Crohn's disease. Aliment Pharmacol Ther. 2019. PMID: 30828852. doi:10.1111/apt.15174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。